Moxifloxacin
- Generic Name
- Moxifloxacin
- Brand Names
- Avelox, Moxeza, Vigamox
- Drug Type
- Small Molecule
- Chemical Formula
- C21H24FN3O4
- CAS Number
- 151096-09-2
- Unique Ingredient Identifier
- U188XYD42P
- Background
Moxifloxacin is a synthetic fluoroquinolone antibiotic agent. Bayer AG developed the drug (initially called BAY 12-8039) and it is marketed worldwide (as the hydrochloride) under the brand name Avelox (in some countries also Avalox) for oral treatment.
- Indication
For the treatment of sinus and lung infections such as sinusitis, pneumonia, and secondary infections in chronic bronchitis. Also for the treatment of bacterial conjunctivitis (pinkeye).
- Associated Conditions
- Acute Exacerbation of Chronic Bronchitis (AECB), Bacterial Conjunctivitis, Community Acquired Pneumonia (CAP), Plague, Postoperative Infections, Postoperative Inflammatory Response, Sinusitis, Skin Infections, Ocular bacterial infections
- Associated Therapies
- -
Adequate Duration of Antibiotic Treatment in Community-acquired Pneumonia With High Risk Class and Adequate Initial Clinical Response
- First Posted Date
- 2018-08-01
- Last Posted Date
- 2019-12-05
- Lead Sponsor
- David Garcia Cinca
- Target Recruit Count
- 424
- Registration Number
- NCT03609099
- Locations
- 🇪🇸
Hospital Galdakao-Usansolo, Galdakao, Bizkaia, Spain
🇪🇸Hospital de Mataró, Mataró, Barcelona, Spain
🇪🇸Hospital Universitario La Fe, València, Valencia, Spain
A Study to Investigate the Effect of JNJ-64565111 on Cardiac Repolarization (Corrected QT Interval) Compared With Placebo in Healthy Adults: a Thorough ECG Study Employing Placebo, JNJ-64565111, and a Positive Control (Moxifloxacin)
- Conditions
- Interventions
- First Posted Date
- 2018-07-30
- Last Posted Date
- 2020-03-03
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 188
- Registration Number
- NCT03606057
- Locations
- 🇺🇸
Celerion, Tempe, Arizona, United States
Evaluate Effects of Meropenem-Vaborbactam on QT/QTc in Healthy Volunteers
- Conditions
- Interventions
- First Posted Date
- 2018-06-20
- Last Posted Date
- 2019-01-10
- Target Recruit Count
- 53
- Registration Number
- NCT03564158
- Locations
- 🇺🇸
Pharmaron Cpc, Inc, Baltimore, Maryland, United States
An Investigational Study of Experimental Medication BMS-986165 in Healthy Participants to Study Electrocardiogram Effects
- Conditions
- Interventions
- First Posted Date
- 2018-05-30
- Last Posted Date
- 2020-01-27
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 84
- Registration Number
- NCT03541564
- Locations
- 🇺🇸
PRA Health Sciences, Lenexa, Kansas, United States
Phase I Study of OPC-61815
- Conditions
- Interventions
- First Posted Date
- 2018-04-27
- Last Posted Date
- 2021-05-10
- Lead Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Target Recruit Count
- 48
- Registration Number
- NCT03510663
- Locations
- 🇯🇵
Kyusyu Region, Fukuoka, Japan
Study to Evaluate the QT / QTc Interval Prolongation Potential of Vericiguat
- Conditions
- Interventions
- First Posted Date
- 2018-04-20
- Last Posted Date
- 2020-04-17
- Lead Sponsor
- Bayer
- Target Recruit Count
- 74
- Registration Number
- NCT03504982
- Locations
- 🇩🇪
Universitätsherzzentrum Freiburg - Bad Krozingen, Bad Krozingen, Baden-Württemberg, Germany
🇳🇱Center for Human Drug Research, Leiden, Netherlands
🇩🇪Universitätsklinikum Heidelberg, Heidelberg, Baden-Württemberg, Germany
A Study of Lasmiditan on the Heart in Healthy Participants
- First Posted Date
- 2018-03-14
- Last Posted Date
- 2020-01-31
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 56
- Registration Number
- NCT03465436
- Locations
- 🇩🇪
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Berlin, Germany
A Two-Part Phase 1 Study to Investigate the Safety and Tolerability of Supratherapeutic Dose of Zanubrutinib and Effect of Zanubrutinib on Cardiac Repolarization in Healthy Subjects
- Conditions
- Interventions
- First Posted Date
- 2018-02-14
- Last Posted Date
- 2020-04-24
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 40
- Registration Number
- NCT03432884
- Locations
- 🇺🇸
Frontage Clinical Services, Inc., Secaucus, New Jersey, United States
A Study To Determine The Effect Of Single-dose PF-04965842 On QTc Interval In Healthy Volunteers Compared With Placebo and Moxifloxacin
- Conditions
- Interventions
- First Posted Date
- 2017-12-29
- Last Posted Date
- 2019-10-14
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 36
- Registration Number
- NCT03386279
- Locations
- 🇧🇪
Pfizer Clinical Research Unit, Brussels, Belgium
Trial to Evaluate the Efficacy, Safety and Tolerability of BPaMZ in Drug-Sensitive (DS-TB) Adult Patients and Drug-Resistant (DR-TB) Adult Patients
- First Posted Date
- 2017-11-09
- Last Posted Date
- 2024-03-07
- Lead Sponsor
- Global Alliance for TB Drug Development
- Target Recruit Count
- 455
- Registration Number
- NCT03338621
- Locations
- 🇿🇦
University of Cape Town Lung Institute, Cape Town, South Africa
🇿🇦Madibeng Centre for Research, Brits, South Africa
🇿🇦CHRU, Empilweni TB Hospital, Port Elizabeth, South Africa
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.